Skip to main content

Cardio Diagnostics Holdings Inc

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

CDIO$1.82+10.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney

Each person whose signature appears below constitutes and appoints Meeshanthini V. Dogan and Elisa Luqman, and each one of them, as her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for her and in their name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitle and CapacityDate
/s/ Meeshanthini V. DoganChief Executive Officer and DirectorApril 1, 2024
Meeshanthini V. Dogan, PhD
/s/ Elisa LuqmanChief Financial Officer and Principal Accounting OfficerApril 1, 2024
Elisa Luqman
/s/ Warren HosseinionDirector (Chairman of the Board)April 1, 2024
Warren Hosseinion, MD
/s/ James IntraterDirectorApril 1, 2024
James Intrater
/s/ Stanley K. LauDirectorApril 1, 2024
Stanley K. Lau
/s/ Oded LevyDirectorApril 1, 2024
Oded Levy
/s/ Robert PhilibertDirectorApril 1, 2024
Robert Philibert, MD
/s/ Paul BurtonDirectorApril 1, 2024
Paul Burton
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.